Next Article in Journal
Brain Metastasis from an Unknown Primary, or Primary Brain Tumour? A Diagnostic Dilemma
Previous Article in Journal
Genomancy: Predicting Tumour Response to Cancer Therapy based on the Oracle Of Genetics
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue 1
10.3747/co.v16i1.406
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Targeting mtor-Dependent Tumours with Specific Inhibitors: A Model for Personalized Medicine based on Molecular Diagnoses

by
L. Furic
,
M. Livingstone
,
R. J. O. Dowling
and
Nahum Sonenberg
*
Goodman Cancer Centre and Department of Biochemistry, McGill University, 1160 avenue Des Pins Ouest, Cancer Pavilion, Room 617, Montreal, QC H3A 1A3, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(1), 59-61; https://0-doi-org.brum.beds.ac.uk/10.3747/co.v16i1.406
Submission received: 2 October 2008 / Revised: 3 November 2008 / Accepted: 4 December 2008 / Published: 1 January 2009

Abstract

Cancer cells are characterized by aberrant growth arising from deregulated signalling pathways. The mammalian target of rapamycin (mtor) pathway integrates multiple growth signals coming from both intracellular and extracellular cues. In this short review, we summarize what is known about the efficacy of targeting the mtor pathway to treat cancer patients, and we explain the rationale behind promising new inhibitors that could show more potent tumour growth inhibition than did the first generation of these drugs.
Keywords: cell signalling; mtor; rapamycin; Lkb1; Fkbp12; tumour growth cell signalling; mtor; rapamycin; Lkb1; Fkbp12; tumour growth

Share and Cite

MDPI and ACS Style

Furic, L.; Livingstone, M.; Dowling, R.J.O.; Sonenberg, N. Targeting mtor-Dependent Tumours with Specific Inhibitors: A Model for Personalized Medicine based on Molecular Diagnoses. Curr. Oncol. 2009, 16, 59-61. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v16i1.406

AMA Style

Furic L, Livingstone M, Dowling RJO, Sonenberg N. Targeting mtor-Dependent Tumours with Specific Inhibitors: A Model for Personalized Medicine based on Molecular Diagnoses. Current Oncology. 2009; 16(1):59-61. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v16i1.406

Chicago/Turabian Style

Furic, L., M. Livingstone, R. J. O. Dowling, and Nahum Sonenberg. 2009. "Targeting mtor-Dependent Tumours with Specific Inhibitors: A Model for Personalized Medicine based on Molecular Diagnoses" Current Oncology 16, no. 1: 59-61. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v16i1.406

Article Metrics

Back to TopTop